Embed Size (px)
Citation preview
Local Attention to Disease and the ���Global Disparity of Health Knowledge���
james evans ([email protected]) jae-mahn shim ([email protected])
University of Chicago john p. ioannidis ([email protected])
Stanford University
Where does knowledge come from?
Where does knowledge come from?
• Needs? • Markets? (needs with $) • Movements? (needs with organization) • Access (mixture of distributions of producers
with needs)
• Idiosyncrasies of scientific advance • Perceptions of scientific generality
National and global health disparities
1) differences in biology (e.g., genetics) 2) differences in socioeconomic experience and
environmental exposures 3) differences in the opportunity to access
health care and receive quality medical attention
National and global health disparities
1) differences in biology (e.g., genetics) 2) differences in socioeconomic experience and
environmental exposures 3) differences in the opportunity to access
health care and receive quality medical attention
Most U.S. examinations emphasize last
Distribution of health knowledge
Less consideration given to the relevance of medical knowledge to the health needs of different groups even if health care was equal Diagnostics and therapies (over)fit to certain bodies / environments with – different disease / disability profiles – different genetic profiles
If so, the same care would not be the same; The same resources would not be equitable
Global inequality of health knowledge
Design 1) Assess global health knowledge Assess how much explained by… 2) the global health burden imposed by these
conditions 3) the global market for therapies 4) the local health burden
Health Knowledge
# articles produced relevant to each disease / condition
f(MEDLINE articles for 111 disorders by researchers in 192 countries) Censorship of non-English, low-circulation research
Health Burden
Disability-adjusted life years (DALYs) • World Health Organization 1990, 2002, 2004
(at global, regional and country level)
• Incorporate cultural values placed on different aspects of physical, mental and social function to convert time spent in various states of health into “healthy year equivalent”
• healthy years lost to disease/disability Alternatives: incidence, prevalence, hospital days, mortality, years lost, …
Linkage"
WHO Global burden of disease codes "" "~ "" "ICD-9 disease and disability codes"
" " "~ "" " "UMLS Metathesaurus"" " " "~"" " " "MeSH headings"" " " " "~ "" " " " "MEDLINE abstracts"
Health Market
The amount of income that could be generated by health from curing disease
= The $ that could be spent on health (if all earned from health were spent on health)
f(GNI per capita * DALY for each disease / country)
Modeling framework
Articlesdt ~ NegativeBinomial(μdt)
Log(μdt) = DALYdt-1 + market sizedt-1 + Articlesdt-1 + Broad disease category + εdt
2005
rese
arch
arti
cles
200
4 lif
e-ye
ars
(DAL
Ys) l
ost (
milli
ons)
050
100
150
200
250
010
,000
20,0
0030
,000
40,0
0050
,00030
0
!"#$%#$&'%($)*+, #'%(($+
-%($+.%/&'*.0"("*.#&1$2)23&%4*+("*.3&5%($+.%/&#$6#"#3&7%$5*++7%)$8&%.0&9*.:&)$."(%/&%.*5%/"$#&1$2)23&'*.)$."(%/&7$%+(&%.*5%/"$#3&!*;.&#,.0+*58&;$+$&*./,%##$##$0&%(&(7$&)/*4%/&/$<$/2
=.>$'("*?#&6%+%#"("' @AB&&&&&&:C2BD
E$#6"+%(*+,&".>$'("*.# BF&&&&&:C2DA
G$+".%(%/&'*.0"("*.# FA&&&&&:C2DH
HF&&&&&:C2A@
IJ".&0"#$%#$# K&&&&&:C2@F
L.".($.("*.%/&".M?+"$# FF&&&&&:C2@H
N$."(*:?+".%+,&0"#$%#$# O@&&&&&:C2@O
=.($.("*.%/&".M?+"$# KO&&&&&:C2@C
!")$#("<$&0"#$%#$# OB&&&&&:C2OC
I$.#$&*+)%.&0"#$%#$# DF&&&&&:C2CA
E$#6"+%(*+,&0"#$%#$# KD&&&&&:C2CP
9%+0"*<%#'?/%+&0"#$%#$#& O@B&&&&&:C2CK
Q.0*'+".$&0"#*+0$+# &HC&&&&&&C2CO
R+%/&'*.0"("*.# &F&&&&&&C2C@
S$?+*:6#,'7"%(+"'&&'*.0"("*.#
&OFF&&&&&&C2CP
-?#'?/*#J$/$(%/&0"#$%#$#& &@D&&&&&&C2CB
-%/").%.(&.$*6/%#5# AB&&&&&&C2OH
T
T
U
U
$10,000
1
10
100
!VWX#&6$+
OCCC&6$*6/$
$100 $1000N!G
6Y2OZ&&6[2OZ&%//&*(7$+#&%+$&6Y2CCO
\
\
\
#'%(($+!"#$%#$&'%($)*+,!VWX#
-25 to -1
6
-16 to -1
3
-13 to -7
-7 to -.6
-.6 to
33 to
77 to
18
18 to 38
38 to 132
132 to 213
213 to 433Infectious parasitic minus Malignant Neoplasm (cancer)
disability adjusted life-years per 1000 people (quantiles)
!"%++7$%3&]=^3&_?4$+'?/*#"#3-%/%+"%3&-$%#/$#3&-$.".)"("#3&$('2
_+%'7$%`4+*.'7?#`/?.)&'%.'$+#3#(*5%'7&'%.'$+3&W"<$+&'%.'$+3&$('2
Osteoarthritis, Rheumatoid arthritis,Gout, Low back pain
Unipolar depressive disorders,Alcohol use disorders, Schizophrenia, etc.
Dental caries, Edentulism,Periodontal disease
Diabetes mellitis, Other endocrinedisorders
Ischaemic heart disease, Cerebrovascular disease, etc.
Chronic obstructive pulmonarydisease, Asthma
Vision disorders (age-related),Hearing loss (adult onset), Cataracts, etc.
Cirrhosis of the liver, Peptic ulcerdisease, etc.
Violence, Self-in!icted injuries
Nephritis and nephrosis, Benignprostatic hypertrophy
Road tra"c accidents, Falls,Fires, Drownings, Poisonings
(Not individually estimated)
Protein-energy malnutrition, Iron-de#ciency anaemia, etc.
Low birth weight, Birth asphyxiaand birth trauma
Lower & upper respiratory infections,Otitis media
!VWX#&&&&&&#/*6$#/*6$a
aN/*4%/&(*(%/&".&5"//"*.&,$%+#
!"#$%#$&'%($)*+, #'%(($+
-%($+.%/&'*.0"("*.#&1$2)23&%4*+("*.3&5%($+.%/&#$6#"#3&7%$5*++7%)$8&%.0&9*.:&)$."(%/&%.*5%/"$#&1$2)23&'*.)$."(%/&7$%+(&%.*5%/"$#3&!*;.&#,.0+*58&;$+$&*./,%##$##$0&%(&(7$&)/*4%/&/$<$/2
=.>$'("*?#&6%+%#"("' @AB&&&&&&:C2BD
E$#6"+%(*+,&".>$'("*.# BF&&&&&:C2DA
G$+".%(%/&'*.0"("*.# FA&&&&&:C2DH
HF&&&&&:C2A@
IJ".&0"#$%#$# K&&&&&:C2@F
L.".($.("*.%/&".M?+"$# FF&&&&&:C2@H
N$."(*:?+".%+,&0"#$%#$# O@&&&&&:C2@O
=.($.("*.%/&".M?+"$# KO&&&&&:C2@C
!")$#("<$&0"#$%#$# OB&&&&&:C2OC
I$.#$&*+)%.&0"#$%#$# DF&&&&&:C2CA
E$#6"+%(*+,&0"#$%#$# KD&&&&&:C2CP
9%+0"*<%#'?/%+&0"#$%#$#& O@B&&&&&:C2CK
Q.0*'+".$&0"#*+0$+# &HC&&&&&&C2CO
R+%/&'*.0"("*.# &F&&&&&&C2C@
S$?+*:6#,'7"%(+"'&&'*.0"("*.#
&OFF&&&&&&C2CP
-?#'?/*#J$/$(%/&0"#$%#$#& &@D&&&&&&C2CB
-%/").%.(&.$*6/%#5# AB&&&&&&C2OH
T
T
U
U
$10,000
1
10
100
!VWX#&6$+
OCCC&6$*6/$
$100 $1000N!G
6Y2OZ&&6[2OZ&%//&*(7$+#&%+$&6Y2CCO
\
\
\
#'%(($+!"#$%#$&'%($)*+,!VWX#
-25 to -1
6
-16 to -1
3
-13 to -7
-7 to -.6
-.6 to
33 to
77 to
18
18 to 38
38 to 132
132 to 213
213 to 433Infectious parasitic minus Malignant Neoplasm (cancer)
disability adjusted life-years per 1000 people (quantiles)
!"%++7$%3&]=^3&_?4$+'?/*#"#3-%/%+"%3&-$%#/$#3&-$.".)"("#3&$('2
_+%'7$%`4+*.'7?#`/?.)&'%.'$+#3#(*5%'7&'%.'$+3&W"<$+&'%.'$+3&$('2
Osteoarthritis, Rheumatoid arthritis,Gout, Low back pain
Unipolar depressive disorders,Alcohol use disorders, Schizophrenia, etc.
Dental caries, Edentulism,Periodontal disease
Diabetes mellitis, Other endocrinedisorders
Ischaemic heart disease, Cerebrovascular disease, etc.
Chronic obstructive pulmonarydisease, Asthma
Vision disorders (age-related),Hearing loss (adult onset), Cataracts, etc.
Cirrhosis of the liver, Peptic ulcerdisease, etc.
Violence, Self-in!icted injuries
Nephritis and nephrosis, Benignprostatic hypertrophy
Road tra"c accidents, Falls,Fires, Drownings, Poisonings
(Not individually estimated)
Protein-energy malnutrition, Iron-de#ciency anaemia, etc.
Low birth weight, Birth asphyxiaand birth trauma
Lower & upper respiratory infections,Otitis media
!VWX#&&&&&&#/*6$#/*6$a
aN/*4%/&(*(%/&".&5"//"*.&,$%+#
!"#"$%"& '()*+ ,-./,.0$.%"1%1& '2)34 5,16'6$"7!"6%.16$011&8%1,$80$&
2)2(
606"-71 '()42 8$,9-%-:1& '2)3; 8$7:&710&8%1,$80$1 2)2+
./":"1&8%10"10& '()33 %$,-'80<%.%0-.="-"0!%"&
'2);4 !,76/&"-8&,$,5/"$=->&."-.0$1&2)2+
!0"1#01& '()3; $/07!"6%.&/0"$6&8%10"10& '2);4 80-:70& 2)2;
?%6"!%-&@80<%.%0-.=&
'()3; 5,%1,-%-:1& '2);;10#<'%-<#%.608%-A7$%01& 2)2;
'()3( 5056%.&7#.0$&8%10"10& '2);( ./$,-%.&,B16$7.6%C0&57#!,-"$=&8%10"10&
2)23
1./%16,1,!%"1%1& '()+D -05/$%6%1&E-05/$,1%1&
'2);2 C%1%,-&8%1,$80$1F&":0'$0#"608& 2)23
8%5/6/0$%"& '()+4 ,6%6%1&!08%"& '2)+* %1./"0!%.&/0"$6&8%10"10& 2)2G
6$=5"-,1,!%"1%1& '()(; 1H%-&8%10"101& '2)+* /0"$%-:&#,11F&"87#6&,-106&
2)2I
#0%1/!"-%"1%1& '()(2 6$%./7$%"1%1& '2)+4 ,01,5/":71&."-.0$&2)2I
5$,60%-'0-0$:=&!"#-76$%6%,-& '()(2 05%#051=& '2)+G
7-%5,#"$&805$011%C0&8%1,$80$1& 2)2I
6$"./,!"& '()2* "550-8%.%6%1& '2)+; ,160,"$6/$%6%1& 2)2*
67B0$.7#,1%1 '()2+ .0$C%>&760$%&."-.0$& '2)+( 8%"B0601&!0##%671& 2)2D
1=5/%#%1& '2)DD '2)+2 #07H"0!%"& 2)2D
A"5"-010&0-.05/"#%6%1&
'2)D* 5,#%,!=0#%6%1& '2)(* %-1,!-%"&J5$%!"$=K& 2)((
'2)D4%-<#"!!"6,$=&/0"$68%10"10& '2)(4 16,!"./&."-.0$& 2)((
L16%!"608&M-<#70-.0&,<&#,::08&NOP&50$&."5%6"&,-&#,::08&8%10"10&O@QR&$"60F&$"-H08&<$,!&!,16&-0:"6%C0&6,&!,16&5,1%6%C0
O%10"10& 1."660$S 1."660$ O%10"10&O%10"10& 1."660$
M,8%-0&80<%.%0-.=
$,"8&6$"<<%.&"..%80-61&
#=!5/"6%.&<%#"$%"1%1&
$10,000
1
10
100
O@QR1&50$(222&50,5#0$100 $1000
NOP
T
U
U
U
U
U
V
V
1#,50 1#,501#,50
J.,-6%-708&,-&<,##,9%-:&5":0K
!"#$$%&#'(!")&#)&) *+,-. /'#0123#( *+,45 3"/$#"6&( +,47
8&$90))")( *+,:; '"<&$(1#61&$( *+,4= &!&690'")3( +,4>
#)1#$"#)")( *+,:5 #)9%3#( *+,4> 30'9"8'&()1'&$2)")( +,4>
'&8$2)?( *+,:7 &6!21$"6&(!")2$!&$)(*+,4> $%&03#92"!(-#$9%$"9")( +,45
'2@&$($&)8"$#92$?("6A&19"26)( *+,;- %?8&$9&6)"<&(%&#$9(
!")&#)&(*+,47 2<#$?(1#61&$( +,4:
B"$9%(#)8%?C"#(D(B"$9%(9$#03#( *+,;: 1&$&B$2<#)10'#$(
!")&#)&(*+,4+ B'#!!&$(1#61&$( +,7+
3&6"6/"9")( *+,;: !")2$!&$(*+,+- B$&#)9(1#61&$( +,77
%22E@2$3(!")&#)&( *+,;4 2B)&))"<&*12380')"<&(!")2$!&$(
*+,+- 3&'#623#(D(29%&$)E"6(1#61&$)(
+,75
'2@(B"$9%(@&"/%9( *+,.- )1%"F28%$&6"#( *+,+- 8$2)9#9&(1#61&$( +,75
GHIJKHLM( *+,.. 8#6"1(!")2$!&$( *+,+; #'12%2'(0)&(!")2$!&$) +,7;
/262$$%2&#( *+,.4 A#'')( *+,+5 8#$E"6)26(!")&#)&( +,7-
*+,.+ 8&$"2!269#'(!")&#)&( *+,+> #'F%&"3&$(D(29%&$!&3&69"#)( +,>>
088&$($&)8"$#92$?"6A&19"26)(
*+,5- !&69#'(1#$"&)( *+,+7 8#61$&#)(1#61&$( +,>.
1#9#$#19)( *+,5= (1"$$%2)")(2A(9%&('"<&$( +,++ 12'26(D($&19031#61&$)((
+,>:
%&8#9"9")(N( *+,5> '?38%23#)(#6!30'9"8'&(3?&'23#
+,++ 12$80)(09&$"(1#61&$(+,>-
<"2'&61& *+,=- B&6"/6(8$2)9#9"1%?8&$9$28%?
+,+4 9$#1%&#JB$261%0)J'06/(1#61&$)
+,=7
A"$&)(
B"82'#$(#AA&19"<&(
O%&(A2''2@"6/(!")2$!&$)(@&$&(26'?(&<#'0#9&!(#9(9%&(/'2B#'('&<&'P(#B!23"6#'(@#''(!&A&19Q(#B2$9"26Q(#6&61&8%#'?Q(1'&A9('"8Q(1'&A9(8#'#9&Q(126/&6"9#'(%&#$9(#623#'"&)Q(!2@6()?6!$23&Q(/209Q(%?8&$9&6)"<&(!")2$!&$)(2A(8$&/6#61?Q('2@(B#1E(8#"6Q(3#9&$6#'(%#&32$$%#/&Q(3#9&$6#'()&8)")Q(3&69#'($&9#$!#9"26(A$23('&#!(&C82)0$&Q(2&)28%#/&#'(#9$&)"#Q(#6!()8"6#(B"A"!#,(
R
8S,+5T((8S,4T((8U,4T((#''(29%&$)(#$&(8S,+4V W
W
W
W
W
X
Y1269"60&!(A$23(8$"2$(8#/&Z
Conclusions
• Global DALYs had NO significant influence on the production of published health knowledge
• Global treatment market for each condition did. • Likely driven by local processes of health research.
– Case reports and clinical trials within countries were strongly guided by local DALYs. Systematic reviews and clinical trials were slightly more responsive to global DALYs, and reviews were not influenced by country conditions.
• Rich and poor countries had very different disease profiles • Rich countries publish much more than poor countries. • Accordingly, conditions common to rich countries
garnered more case and clinical research than those common to poor countries.
Implications
Many health needs in poor countries do not attract attention among rich country researchers Rich country researchers dominate the production of global health knowledge • How much health knowledge relevant to poor country
diseases? • What is the efficacy of health care resources currently
extended to poor populations? Inequality of health knowledge should be addressed as an additional dimension of current global health inequality
Limitations
• The empirical distribution of “other papers”: Human vs. Mammal models vs. Yeast
• Citations with longer lag to enable Fixed-effect modeling and tighter identification
• GNI/GDP adjusted for purchasing power parity • More (recent) years • National health research funding data
Next Steps
Detailed institutional configuration: OECD countries funding by area United States (with Bhaven Sampat) funding, activism/earmarks, expenditures, medical exposures, scientific relevance/generality, opportunistic swarming, etc.
Thank you
• Program on Health and health policy research for disadvantaged populations at the Center for Health Administration
